Dongxing Medical (301290.SZ) plans to establish a joint venture to establish Changzhou Lingnao Intelligent Technology Co., Ltd.

Zhitong Finance App News, Dongxing Healthcare (301290.SZ) announced that the company plans to jointly fund the establishment of Changzhou Lingnao Intelligent Technology Co., Ltd. with Guoxing Investment, which is directly controlled by the controlling shareholder and actual controller Mr. Wan Shiping. The registered capital of Lingnao Intelligence is 30 million yuan, of which the company plans to invest 20 million yuan in monetary terms, accounting for 66.67% of the registered capital of Lingnao Intelligence; Guoxing Investment plans to invest 10 million yuan in monetary terms, accounting for 33.33% of the registered capital of Lingnao Intelligence. After the investment is completed, Lingnao Intelligence will be included in the scope of the company's consolidated statements and become a holding subsidiary of the company.

This investment is the strategic layout of the company in response to the national brain-computer interface industry policy, extending the industrial chain, and cultivating new profit growth points. The company plans to gather science and innovation talents through smart brain intelligence, carry out industry-university-research cooperation with well-known universities and research institutes, rely on the company's R&D, production and clinical transformation capabilities in the field of medical devices, expand its layout in brain-computer interface, neuroscience, psychiatric diseases and other medical and health care fields, and promote the integration and collaboration of cutting-edge technology and existing business to cultivate new profit growth points.

This investment is highly correlated with the company's current main business. The target company mainly studies brain-computer interface products for medical purposes. Its business scope also includes the production and operation of Class I, Class II and Class III medical devices. It is on the same track as the company's long-term medical device R&D, registration, production and clinical transformation business, and can share product registration, clinical resources, quality compliance systems and customer channels. The company has a natural extension and cutting-edge layout in the direction of brain-computer interface and neuroscience based on the main medical device business, rather than crossing borders into fields unrelated to the main business, which is conducive to technological collaboration and industrial chain extension.